Corient Private Wealth LLC Purchases 29,210 Shares of Illumina, Inc. $ILMN

Corient Private Wealth LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 233.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,737 shares of the life sciences company’s stock after purchasing an additional 29,210 shares during the quarter. Corient Private Wealth LLC’s holdings in Illumina were worth $5,475,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund acquired a new position in shares of Illumina in the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC grew its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in Illumina during the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina during the 4th quarter valued at $26,000. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling at Illumina

In related news, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $177.65 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a 50 day simple moving average of $148.74 and a 200 day simple moving average of $137.38. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $182.84. The firm has a market cap of $26.88 billion, a P/E ratio of 32.30, a P/E/G ratio of 3.28 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

ILMN has been the subject of several research analyst reports. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Guggenheim increased their target price on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Citigroup lifted their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $143.56.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.